CureVac N.V.: 5%+ holders

As of November 6, 2026, CureVac N.V. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 6 filings are on record since August 1, 2025 (Schedule 13D/A, December 12, 2025).

Sell to companies like CureVac N.V? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2025-12-12 · Holder: KfW · Percent: 0% · SCHEDULE 13D/A
• Filed 2025-12-12 · Holder: dievini Hopp BioTech holding GmbH & Co. KG · Percent: 0% · SCHEDULE 13D/A
• Filed 2025-12-12 · Holder: Dr. Matthias Hothum · Percent: 0% · SCHEDULE 13D/A
• Filed 2025-12-05 · Holder: GSK plc · Percent: 0% · SCHEDULE 13D/A
• Filed 2025-08-13 · Holder: GSK plc · Percent: 74% · SCHEDULE 13D

CureVac N.V. has 6 Schedule 13D or 13G filings on record since 2025-08-01. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind CureVac N.V. and the warning signs.

See CureVac N.V.'s free Snapshot Watch CureVac N.V.: email me the next time it files something

Free to see. No signup.

Want the whole picture on CureVac N.V.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on CureVac N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CureVac N.V. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

KfW

Reference is made to that certain (i) Purchase Agreement by and between BioNTech SE, a European stock corporation (the "Buyer") and the Issuer dated June 12, 2025 (the "'Purchase Agreement") and the exchange offer described therein (the "Exchange Offer") and (ii) termination agreement of the Shareholders' Agreement dated October 29, 2025 by and among, KfW, dievini, Zweite DH Verwaltungs GmbH, 4H invest GmbH, Bohlini Invest GmbH, MH-LT Investments GmbH and certain other parties (the "Termination Agreement"). KfW has tendered all of its Common Shares into the Exchange Offer pursuant to that certain Tender and Support Agreement dated July 31, 2025 by and between KfW and the Buyer (the "Tender and Support Agreement"), with respect to the Common Shares held by KfW. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Common Shares held by KfW were accepted for exchange and transferred to the Buyer in a capital increase for the issue of shares in Buyer underlying the American Depository Shares of Buyer offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, KfW no longer beneficially owns, or otherwise holds, any securities of the Issuer. KfW expects to receive full consideration to which it is entitled under the Exchange Offer (the "Completion") on or about December 15, 2025. Pursuant to the Termination Agreement, the Shareholders' Agreement will terminate upon the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-12; the filing has the rest

GSK plc

Item 4 of the Schedule 13D is hereby amended by adding the following: Pursuant to the terms of the Tender and Support Agreement, GGL tendered all Common Shares held by it in the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Common Shares held by GGL were accepted for exchange on December 3, 2025. As a result, GSK, through its wholly-owned indirect subsidiary GGL, no longer beneficially owns, or otherwise holds, any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-05

dievini Hopp BioTech holding GmbH & Co. KG

The Reporting Persons have tendered all of their Shares into the Exchange Offer pursuant to the Tender and Support Agreement. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depository Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer. The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025. Pursuant to an agreement dated October 29, 2025 among the parties to the Shareholders' Agreement, the Shareholders' Agreement will terminate upon the Completion. The foregoing description of the Tender and Support Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to such agreement. A copy of the form of Tender and Support Agreement is incorporated by reference to Exhibit 99.3 to the Reporting Persons' Amendment 8 to Schedule 13D filed with the SEC on June 16, 2025.Item 4 of the SCHEDULE 13D/A filed 2025-12-12

Dr. Matthias Hothum

The Reporting Persons have tendered all of their Shares into the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depository Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer. The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025.Item 4 of the SCHEDULE 13D/A filed 2025-12-12

Timeline

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for CureVac N.V.. With no account yet, you sign up free and land on the result.

• Get an alert when CureVac N.V. is mentioned again
• Find former CureVac N.V. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes